The AASM recognizes the patient benefits of TPNS, highlighting the improvements in central event indices, oxygen desaturation index, quality of life, and several sleep architecture measures. TPNS is recommended both in primary central sleep apnea and central sleep apnea due to heart failure.
Analysis conducted on a hierarchical endpoint comprised of mortality, HF hospitalization, and health status shows that patients treated with phrenic nerve stimulation may be nearly five times as likely to experience a clinical benefit compared to those in the control group.
Expanded insurance coverage now available in Utah, Idaho and Nevada
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).